- Home
- HITI vs TNGX Comparison
HITI vs TNGX Comparison
Compare HITI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HITI
- TNGX
- Stock Information
- Founded
- HITI 2009
- TNGX 2014
- Country
- HITI Canada
- TNGX United States
- Employees
- HITI N/A
- TNGX N/A
- Industry
- HITI
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- HITI
- TNGX Health Care
- Exchange
- HITI Nasdaq
- TNGX Nasdaq
- Market Cap
- HITI 217.9M
- TNGX 248.2M
- IPO Year
- HITI N/A
- TNGX N/A
- Fundamental
- Price
- HITI $2.31
- TNGX $2.21
- Analyst Decision
- HITI Strong Buy
- TNGX Strong Buy
- Analyst Count
- HITI 1
- TNGX 6
- Target Price
- HITI $4.50
- TNGX $12.20
- AVG Volume (30 Days)
- HITI 293.6K
- TNGX 3.5M
- Earning Date
- HITI 06-12-2025
- TNGX 05-12-2025
- Dividend Yield
- HITI N/A
- TNGX N/A
- EPS Growth
- HITI N/A
- TNGX N/A
- EPS
- HITI N/A
- TNGX N/A
- Revenue
- HITI $370,825,186.00
- TNGX $40,990,000.00
- Revenue This Year
- HITI $12.43
- TNGX N/A
- Revenue Next Year
- HITI $11.39
- TNGX N/A
- P/E Ratio
- HITI N/A
- TNGX N/A
- Revenue Growth
- HITI 7.84
- TNGX 10.09
- 52 Week Low
- HITI $1.57
- TNGX $1.03
- 52 Week High
- HITI $3.62
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- HITI 47.92
- TNGX 62.72
- Support Level
- HITI $2.17
- TNGX $1.93
- Resistance Level
- HITI $2.35
- TNGX $2.67
- Average True Range (ATR)
- HITI 0.08
- TNGX 0.39
- MACD
- HITI -0.02
- TNGX 0.07
- Stochastic Oscillator
- HITI 41.42
- TNGX 55.38
About HITI High Tide Inc.
High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically integrated company in the Canadian cannabis market with various brands in its portfolio such as Canna Cabana, Fastendr, Queen of Bud, Grasscity, Daily High Club, Famous Brandz, and others. The company's reportable operating segments are; Bricks and mortar which generates maximum revenue, and E-commerce. Geographically, it derives maximum revenue from its business in Canada followed by the United States of America, and other international markets.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.